Showing 2701-2710 of 5621 results for "".
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturinghttps://modernod.com/news/ocugen-and-cansinobio-enter-strategic-partnership-for-gene-therapy-co-development-and-manufacturing/2476929/Ocugen has entered into a strategic partnership with CanSino Biologics on Ocugen’s gene therapy pipeline product candidates for inherited retinal diseases, which are currently in development with Schepens Eye Research Institute of Massachusetts Eye and Ear, an affiliate of Harvard Medical Schoo
- Bausch + Lomb Enters Licensing Agreement With Intraocular Lens Design Group Tatvum Researchhttps://modernod.com/news/bausch-lomb-enters-licensing-agreement-with-intraocular-lens-design-group-tatvum-research/2476928/Bausch + Lomb announced that it has entered into a licensing agreement with Tatvum Research, a company focused on IOL development and design. Financial terms of the deal were not disclosed. The agreement provides Bausch + Lomb with worldwide commercial rights to new IOL designs for
- Santen Expands Into Surgical Devices and Publishes Real-World Evidence in Dry Eye Diseasehttps://modernod.com/news/santen-expands-into-surgical-devices-and-publishes-real-world-evidence-in-dry-eye-disease/2476923/In addition to launching a new monofocal, hydrophobic IOL, xact Mono-EDoF, a panel of experts including Ike K. Ahmed, reviewed current surgical techniques and introduced Santen’s Preserflo MicroShunt device at the recent ESCRS meeting in Paris. Preserflo MicroShunt is a surgical dev
- EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Aca
- Tangible Science and VSP Optics Co-develop New Daily Disposable Silicone Hydrogel Contact Lenshttps://modernod.com/news/tangible-science-and-vsp-optics-co-develop-new-daily-disposable-silicone-hydrogel-contact-lens/2476916/Tangible Science announced the launch of Unity BioSync contact lenses, which the company is describing as the first daily disposable silicone hydrogel contact lens featuring a modified formula of the patented Tangible Hydra-PEG polymer technology that is bonded to the surface of the lens. Co-deve
- Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/Ocular Therapeutix announced that it has dosed the first patients in its phase 3 clinical trial of Dextenza for the treatment of symptoms of allergic conjunctivitis. Allergic conjunctivitis refers to inflammation of the conjunctiva of the eye caused by an allergic reaction–generally from airborne
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseaseshttps://modernod.com/news/boehringer-ingelheim-partners-with-inflammasome-therapeutics-to-develop-novel-therapies-for-patients-with-retinal-diseases/2476903/Boehringer Ingelheim and Inflammasome Therapeutics announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelhei
- Canon Xephilio OCT-A1 Device Receives FDA 510(k) Clearancehttps://modernod.com/news/canon-xephilio-oct-a1-device-receives-fda-510k-clearance/2476889/Expanding the company’s lineup of eye care product offerings, Canon USA announced the new intuitive Xephilio OCT-A1 device. This device features automated acquisition functionality, which makes it easy to use, allowing healthcare professionals to obtain high